GW&K Investment Management LLC Buys 668,881 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• GW&K Investment Management increased its stake by 139% in Q3, buying an additional 668,881 shares to hold 1,150,169 shares (about 1.19% of Ultragenyx) valued at roughly $34.6 million.
• Ultragenyx faces a significant legal overhang—multiple class-action filings and solicitations allege misstatements tied to the Phase III setrusumab failure, with an April 6, 2026 lead‑plaintiff deadline highlighting potential litigation risk.
• Analysts have cut price targets recently though the consensus remains a Moderate Buy with an average target of $68.29; the stock trades near $21.46 and the company reported negative EPS (-$1.29) despite year‑over‑year revenue growth.

GW&K Investment Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 139.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,150,169 shares of the biopharmaceutical company's stock after purchasing an additional 668,881 shares during the quarter. GW&K Investment Management LLC owned approximately 1.19% of Ultragenyx Pharmaceutical worth $34,597,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Rafferty Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 93.0% in the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company's stock worth $4,707,000 after buying an additional 75,388 shares during the period. Huntington National Bank raised its holdings in shares of Ultragenyx Pharmaceutical by 56.2% in the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 393 shares in the last quarter. Quantbot Technologies LP purchased a new stake in Ultragenyx Pharmaceutical in the third quarter worth about $188,000. Xponance Inc. grew its holdings in Ultragenyx Pharmaceutical by 3.1% during the 3rd quarter. Xponance Inc. now owns 13,494 shares of the biopharmaceutical company's stock worth $406,000 after acquiring an additional 406 shares in the last quarter. Finally, DNB Asset Management AS grew its holdings in Ultragenyx Pharmaceutical by 18.7% during the 3rd quarter. DNB Asset Management AS now owns 17,479 shares of the biopharmaceutical company's stock worth $526,000 after acquiring an additional 2,759 shares in the last quarter. 97.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on RARE shares. Robert W. Baird reduced their price target on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an "outperform" rating for the company in a report on Tuesday, December 30th. Wedbush reissued a "neutral" rating and issued a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Wells Fargo & Company dropped their target price on Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an "overweight" rating on the stock in a research report on Tuesday, December 30th. HC Wainwright cut their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a "buy" rating on the stock in a report on Tuesday, February 17th. Finally, Jefferies Financial Group reduced their price target on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a "buy" rating for the company in a research report on Tuesday, December 30th. Sixteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $68.29.

Ultragenyx Pharmaceutical Trading Down 1.6%

Shares of RARE stock opened at $21.46 on Friday. Ultragenyx Pharmaceutical Inc. has a 12-month low of $18.41 and a 12-month high of $42.37. The business's fifty day simple moving average is $23.30 and its 200-day simple moving average is $29.14. The company has a market cap of $2.07 billion, a PE ratio of -3.67 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analysts' expectations of $199.60 million. During the same quarter last year, the firm earned ($1.39) earnings per share. The firm's quarterly revenue was up 25.5% compared to the same quarter last year. On average, equities analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total value of $1,240,411.20. Following the completion of the sale, the chief executive officer directly owned 658,994 shares in the company, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 1,635 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $22.40, for a total transaction of $36,624.00. Following the transaction, the chief financial officer owned 85,034 shares in the company, valued at $1,904,761.60. The trade was a 1.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 108,039 shares of company stock valued at $2,506,945. Insiders own 5.50% of the company's stock.

Key Ultragenyx Pharmaceutical News

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: Regulatory/procedural deadline — multiple firms are reminding eligible purchasers of the April 6, 2026 lead plaintiff deadline for the class action; this is a procedural notice but focuses attention on potential litigation exposure. ROSEN Deadline Notice
• Negative Sentiment: Class action filings and widespread solicitations — multiple law firms (Pomerantz, Robbins Geller, ClaimsFiler, Bronstein Gewirtz & others) have circulated notices and at least one suit has been filed alleging misstatements/omissions tied to setrusumab results; that raises potential legal and financial risk. Pomerantz Notice
• Negative Sentiment: Legal overhang amplified by media/legal alerts — additional reminders from ClaimsFiler, Robbins LLP, Furuqi & Furuqi and others increase publicity around the suit and the potential damages/settlement risk. ClaimsFiler Alert
• Negative Sentiment: Prior clinical setback cited by plaintiff counsel — Levi & Korsinsky highlights the company’s >40% decline after a Phase III setrusumab failure disclosure, framing the litigation narrative and reinforcing investor concern about program and disclosure risk. Levi & Korsinsky Alert
• Negative Sentiment: Insider selling — CFO Howard Horn disclosed multiple recent sales (including March 3 sale of 1,635 shares), feeding short‑term sentiment pressure even if not necessarily signaling company fundamentals. Insider Trades Report

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.